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A 31-year old man with a right testicular mass was evalu-
ated at the urology department. Scrotal ultrasound re-
vealed a right hypervascolarized testicular mass of 8,5cm. 
Alpha fetoprotein and bHCG were elevated at 821kU/l 
(N<5kU/l) and 8200U/l (N<5U/l) respectively. The tho-
racic-abdominal computed tomography scan showed an 
enlarged retroperitoneal lymph node of 32mm (Figure 1). 
The past medical history was notable for a right orchi-
dopexie at age of 5 years and an Asperger syndrome, an 
autism spectrum disorder that is characterized by signifi -
cant diffi culties in social interaction, along with restricted 
and repetitive patterns of behavior and interests. It differs 
from other autism spectrum disorders by its relative pres-
ervation of linguistic and cognitive development.
The patient underwent an inguinal and scrotal orchidec-
tomy. Tumor markers descended signifi cantly but did not 
normalize; the patient was considered a stage II, «good 
prognosis» metastatic germ cell tumor (IGCCCG prog-
nostic grouping classifi cation) and scheduled according to 
the European Consensus Guideline for 3 cycles of bleomy-
cin, etoposide and cisplatin (BEP)1,2. Just before the 2nd 
cycle, the patient complained about nausea and headache 
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with photophobia. Physical exam was unremarkable with 
the exception of moderate scleral injection. A viral infec-
tion was suspected. These symptoms improved during 
the second course of chemotherapy but the patient pre-
sented a generalized seizure while leaving the hospital on 
day 5. Urgent CT and MRI scan showed a cerebral sinus 
thrombosis and ruled out brain metastasis (Figure 2). No 
smoking history or cardiovascular risk factors were iden-
tifi ed and further investigations ruled out heart disease 
and coagulopathy. Anticoagulation and anti-convulsant 
treatments were introduced. The patient completed his 
chemotherapy at full dose archiving complete remission.
Discussion
BEP is the cornerstone in the management of metastatic 
germ cell tumors. Acute toxicities are tiredness, leucope-
nia, nausea, alopecia, neuropathie and kidney defi ciency 
due to cisplatine. Thrombotic occlusions of peripheral ar-
teries during chemotherapy have been reported in a num-
ber of patients with germ cell cancer.3-6 Only few cases 
with cerebral venous sinus thrombosis during chemother-
apy have been reported and none to our knowledge did 
involve patients with testicular germ cell tumor.7  
Cerebral vein and dural sinus thrombosis (CVT) are less 
common than most other types of stroke. Large sinuses 
such as the superior sagittal sinus are most frequently in-
volved. Extensive collateral circulation within the cerebral 
venous system allows for a signifi cant degree of compensa-
tion in the early stages of thrombus formation. Systemic 
infl ammatory diseases and inherited as well as acquired 
coagulation disorders are frequent causes, although in up 
to 30% of cases no underlying cause can be identifi ed. The 
spectrum of clinical presentations ranges from headache 
with papilloedema to focal defi cit, seizures and coma, and 
it’s more common in women than men, with a female to 
male ratio of 3:1.
Figure 1: Retro-peritoneal lymph node methastasis. Figure 2: Cerebral sinus thrombosis
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Cardiovascular risk factors, such as smoking and pre-ex-
isting arterial disease, are frequently mentioned as risk 
factors for the development of thromboembolic events 
cancer patients.  Furthermore, several other mechanisms 
have been hypothesized, including high dose cortister-
oids, cisplatin-related, several mutations (factor V Leiden 
and prothrombin ).8,9
It is known that high doses of corticosteroids (≥ 80 mg 
dexamethasone per cycle) are independent risk factors 
for the development of thromboembolic events in germ 
cell cancer patients undergoing chemotherapy. This is in 
agreement with several reports about the hypercoagulable 
state and the occurrence of thromboembolic events of pa-
tients with Cushing’s syndrome.10  Various mechanisms 
contribute to the hypercoagulability induced by cortico-
steroids : inhibition of blood fi brinolytic activity and de-
crease platelet count and levels of the clotting factor VIII/
von Willebrand factor complex. Moreover, corticosteroids 
are known to decrease cerebral blood fl ow by their direct 
vasoconstrictive effect on cerebral blood vessels, increase 
blood pressure, and decrease the clearance rate of activated 
clotting factors by reticuloendothelial blockade. 
Secondary TE events constitute well recognized compli-
cation of chemotherapy.11 Cisplatin have been implicated 
for the occurrence of venous and arterial thrombotic com-
plications in patients with disseminated germ cell can-
cer.  There are a lot of hypothesis about the mechanism of 
cisplatin-induced TE events, including cisplatin-related 
hypomagnesemia, drug-induced damage of the vascular 
endothelium which would activate the coagulation cas-
cade, and elevation of von Willebrand factor plasma lev-
els.12 Cisplatin is thought to initiate degenerative process-
es of vessel walls, thus causing occlusive vascular disease 
in the long run. All types of arteries may be involved, 
and there is sound evidence for an excess of myocardial 
infarctions, arterial hypertension, and cerebral strokes. 
Recently, a metanalysis showed that cardiovascular com-
plications secondary to cisplatin-based chemotherapy may 
also occur early during the application of systemic ther-
apy or immediately thereafter. Such complications from 
cisplatin-based chemotherapy have been encountered in 
several malignancies, but patients with germ-cell tumors 
are at higher risk for thrombo-embolic events than pa-
tients with non germ-cell tumors while on cisplatin-based 
chemotherapy and the risk can be predicted by the serum 
lactate dehydrogenase (LDH) levels and the body surface 
area.13  
We reported a young patient with a cerebral venous sinus 
thrombosis during chemotherapy for germinal cancer.  He 
had no prior history of vascular thrombosis. Investigation 
for systemic vasculitis, disseminated intravascular coagu-
lation, anticardiolipin antibodies and thrombophilia was 
negative and the only risk factor for CST identifi ed was 
the chemotherapy regimen.  Although clinical thrombo-
embolism occurs in as many as 11 percent of patients with 
cancer and is the second leading cause of death in patients 
with overt malignant disease, there is not enough infor-
mation available at this time to recommend for or against 
the use of anticoagulation to prevent VTE in ambulatory 
cancer patients receiving chemotherapy. The 2007 ASCO 
guidelines, the 2008 ACCP guidelines, and a 2009 Con-
sensus Statement of major guidelines panels do not rec-
ommend routine VTE prophylaxis in ambulatory patients 
with cancer, except for those with multiple myeloma re-
ceiving thalidomide or lenalidomide and chemotherapy or 
dexamethasone.14-16 Randomized studies comparing low 
molecular weight (LMW) heparin to placebo in cancer 
patients receiving chemotherapy are ongoing, but results 
from a large randomized controlled study indicated that 
use of the LMW heparin nadroparin did not signifi cantly 
improve median overall survival in 503 patients with ad-
vanced cancer (prostate, pancreas, non-small cell lung can-
cer) over those not receiving this agent (13.1 versus 11.9 
months, respectively)17.
Clinicians treating patients with germ cell cancers should 
be aware about the increased thromboembolic event rate 
and should have a low threshold to use prophylactic low 
molecular weight heparin18. 
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NOUVEAUTÉ: Atelier interprofessionnel de psycho-oncologie en français
La Ligue suisse contre le cancer (LSC) et la Société suisse de psycho-oncologie (SSPO) proposent depuis plusieurs 
années une formation continue interprofessionnelle de psycho-oncologie en langue allemande. Cette année, pour 
la première fois, un atelier interprofessionnel est proposé en français. L’objectif: sensibiliser différents groupes 
professionnels actifs dans les soins oncologiques de base aux multiples aspects de la psycho-oncologie, tout en 
leur permettant d’acquérir de nouvelles connaissances et de désamorcer certaines diffi cultés. Il s’agit d’offrir aux 
personnes atteintes de cancer et à leurs proches un soutien psychosocial de qualité.
Intitulé «Introduction à la psycho-oncologie: éléments clefs», l’atelier abordera des thèmes comme l’adaptation 
des patients à la maladie, les troubles psychiatriques les plus fréquents, les bases de la communication avec le patient 
ainsi que les éléments clefs des interventions psychothérapeutiques.
Lieu et date
Le 8 septembre 2011, de 8 h 30 à 16 h 45 au Centre hospitalier universitaire vaudois (CHUV), Rue du Bugnon 21, 
Lausanne. 
Chargés de cours
Prof. Dr med. Friedrich Stiefel, psychiatre et chef du Service de psychiatrie de liaison, CHUV.
Sonia Krenz, psychologue associée (FSP), Service de psychiatrie de liaison, CHUV.
Public cible
L’atelier s’adresse à un public interdisciplinaire composé de différents spécialistes dans le domaine de l’oncologie: 
psychologues, médecins, travailleurs sociaux, spécialistes en soins infi rmiers, théologiens, etc.
Conditions d’admission
Tous les participants doivent travailler dans un service ou une consultation ambulatoire d’oncologie, en contact 
direct avec des personnes atteintes d’un cancer. 
Coûts
Frais d’inscription: CHF 400.–.
Contact
Ligue suisse contre le cancer, Valentina Celio Moser, case postale 8219, 3001 Berne
tél. 031 389 91 26, fax 031 389 91 60, valentina.celio@liguecancer.ch
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